- Home
- PLAY vs TNGX Comparison
PLAY vs TNGX Comparison
Compare PLAY & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLAY
- TNGX
- Stock Information
- Founded
- PLAY 1982
- TNGX 2014
- Country
- PLAY United States
- TNGX United States
- Employees
- PLAY N/A
- TNGX N/A
- Industry
- PLAY Restaurants
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- PLAY Consumer Discretionary
- TNGX Health Care
- Exchange
- PLAY Nasdaq
- TNGX Nasdaq
- Market Cap
- PLAY 887.6M
- TNGX 1.0B
- IPO Year
- PLAY 1995
- TNGX N/A
- Fundamental
- Price
- PLAY $13.14
- TNGX $8.04
- Analyst Decision
- PLAY Hold
- TNGX Strong Buy
- Analyst Count
- PLAY 8
- TNGX 6
- Target Price
- PLAY $27.43
- TNGX $10.80
- AVG Volume (30 Days)
- PLAY 1.5M
- TNGX 4.4M
- Earning Date
- PLAY 12-09-2025
- TNGX 11-04-2025
- Dividend Yield
- PLAY N/A
- TNGX N/A
- EPS Growth
- PLAY N/A
- TNGX N/A
- EPS
- PLAY 0.26
- TNGX N/A
- Revenue
- PLAY $2,112,500,000.00
- TNGX $66,501,000.00
- Revenue This Year
- PLAY $2.83
- TNGX $20.41
- Revenue Next Year
- PLAY $5.65
- TNGX N/A
- P/E Ratio
- PLAY $51.18
- TNGX N/A
- Revenue Growth
- PLAY N/A
- TNGX 53.29
- 52 Week Low
- PLAY $13.13
- TNGX $1.03
- 52 Week High
- PLAY $43.73
- TNGX $9.70
- Technical
- Relative Strength Index (RSI)
- PLAY 24.20
- TNGX 50.66
- Support Level
- PLAY $17.19
- TNGX $7.12
- Resistance Level
- PLAY $14.56
- TNGX $8.17
- Average True Range (ATR)
- PLAY 0.86
- TNGX 0.71
- MACD
- PLAY -0.26
- TNGX -0.09
- Stochastic Oscillator
- PLAY 0.25
- TNGX 49.07
About PLAY Dave & Buster's Entertainment Inc.
Dave & Buster's Entertainment Inc owns and operates nearly a hundred entertainment and dining establishments in the United States where customers can eat, drink, play games, and watch televised sports. Each store offers a full menu of entries and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. It derives maximum revenue from Entertainment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.